Novo Nordisk plans major investment in new business areas  

2006.03.28
Denmark's Novo Nordisk, a world leader in diabetes care, plans to invest substantially in developing new business areas for the treatment of cancer and inflammatory diseases such as rheumatoid arthritis

Danish healthcare company Novo Nordisk, a world leader in diabetes care, plans to invest substantially in developing new business areas for the treatment of cancer and inflammatory diseases such as rheumatoid arthritis. In 2008, the company expects to have up to 10 candidate drugs in initial test trials in humans. Terje Kalland, who heads a team of 330 biopharmaceutical research scientists in Novo Nordisk, comments:

"We want to create a critical mass of development projects in cancer and inflammation. That means a suitable number to ensure a continuity of new products that reach the market. I would rather not disclose too many details of the objectives in our strategy plan, but in 2008 we must have a critical mass in the pipeline."

Novo Nordisk has this year entered two collaboration agreements regarding development of drug candidates, one of them earlier this month with Argos Therapeutics. Argos has licensed antibody technology to Novo Nordisk for research and development of a treatment for autoimmune disorders. The news was reported by financial daily newspaper Børsen.

Novo Nordisk is headquartered in Bagsværd, north of Copenhagen, and employs 22,000 people in 79 countries. The company has the broadest product portfolio in the diabetes industry, including advanced products in the area of insulin delivery systems. It also has a leading position in areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London.

Link > Novo Nordisk 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×